Global health challenges
Neglected tropical diseases
Neglected Tropical Diseases
Adding to their nearly 200 R&D projects, our members are also involved in over 40 partnerships to support capacity-strengthening in developing economies, and continue to deliver on their 2012 pledge of 1.4 billion annual treatments in donations.
Stopping neglected diseases is achievable. Success relies on a multi-stakeholder approach to not only drive further research but also integrate environmental improvements, boost capacity-strengthening efforts, improve health policies, provide better screening and broaden availability of quality, safe and effective medicines.
Our industry is currently working on 186 R&D projects to develop new or improved medicines and vaccines for 11 neglected conditions that each year kill or disable millions of people in low- and middle-income countries. Of the 186 treatments or vaccines R&D projects, 28 are undergoing early stage clinical trials, while 10 currently go through the final stages of demonstrating their efficacy, quality, and safety. 164 (88%) R&D projects for neglected diseases are collaborative efforts, involving partnerships between IFPMA member companies and more than 80 partners from universities, public and private sector institutes and non-governmental organizations.
According to the latest G-Finder Report, our industry invested USD 534 million in neglected diseases R&D in 2014, a 28% increase compared the previous year.
Solving major global health issues like NTDs requires concerted action and commitment from a broad range of partners. As one the WHO’s “community of partners” fighting NTDs, our industry is committed to help end this suffering by bringing its unique expertise in pharmaceutical innovation to the fight against NTDs. For decades individual pharmaceutical companies have researched, developed, and donated medicines to fight disease and improve patients’ lives. In January 2012 the research-based pharmaceutical industry jointly pledges a further 14 billion treatments to help end these debilitating diseases (London Declaration). Our industry continues to deliver on its pledge of 1.4 billion annual treatments through 2020 to control or eliminate the nine neglected diseases responsible for more than 90% of the global neglected diseases burden. These donations support WHO’s mass drug administration programs for neglected diseases.
Finally, IFPMA member companies are also involved in over 40 partnerships to support capacity-strengthening the projects that aim to bolster local health systems and capacity, as well as provide safe water and sanitation, and public awareness on disease prevention.
The TDR Clinical Research and Development Fellows (CDF) program, which began in 1999 with the support of IFPMA, gives postgraduate fellows from hospitals, academic and research institutions the opportunity to spend 12 months working in the clinical department of a host pharmaceutical company, product development partnership or research institution.
in industry funding for neglected diseases R&D in 2014
14 billion treatments
donated this decade to support the elimination or control of 9 key neglected diseases
40 health partnerships programs
combine prevention, training and treatment